Acceleron Pharma and Celgene have signed their second collaboration in anaemia, this time an agreement potentially worth US$242 M to develop and commercialise Acceleron’s ACE-536, a novel protein therapeutic for the treatment of myelodysplastic syndromes. The two companies have been collaborating on the development and commercialisation of Acceleron’s sotatercept (ACE-011), a biological drug candidate for chemotherapy-induced anaemia and chronic kidney disease-related anaemia, since 2008.